glp-1 receptor agonist pancreatitis risk meta-analysis Why Does Cause Pancreatitis? Factors Explained GLP1 Receptor Agonists—Effects beyond Obesity
Description
ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin-receptor blockers Postop, Postprocedural
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a meta-analysis
Wen B, Zhao L, Zhao H, Wang X
doi: 10.1038/s41598-017-16488-x [DOI] [PMC free article] [PubMed] [Google Scholar] 199
Eli Lilly is evaluating its lead asset, tirzepatide , in phase III obesity drug clinical trials for the reduction of morbidity and mortality in obesity
Targeting the GLP-1/ GLP-1R axis to treat osteoarthritis: A new opportunity
